Evidence map›Paper›PMID 21720206›Full record

ReviewJournal of endocrinological investigation

Hypogonadism and metabolic syndrome.

G Corona, G Rastrelli, A Morelli, L Vignozzi, E Mannucci, M Maggi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of endocrinological investigation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Metabolic syndrome and male fertility disorders: Is there a causal link?Reviews in endocrine & metabolic disorders · 2021
    Review
  12. Review
  13. HIV and Sexual Dysfunction in Men.Journal of clinical medicine · 2021
    Review
  14. Metabolic Syndrome and Reproduction.International journal of molecular sciences · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

G CoronaAndrology and Sexual Medicine Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.
G Rastrelli
A Morelli
L Vignozzi
E Mannucci
M Maggi
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relationship between metabolic syndrome (MetS), male hypogonadism and their possible interaction in cardiovascular (CV) risk stratification are not completely understood.

aimWe reviewed relationships between testosterone (T) and MetS emphasizing their possible interaction in the pathogenesis of CV diseases. MATERIALS AND

methodsA systematic search of published evidence was performed using Medline (1969 to January 2011).

resultsCross-sectional data have shown that subjects with MetS have lower levels of total T (TT) (about 3 nmol/l), as hypogonadism is more evident in subjects with than in those without erectile dysfunction (ED) than in those without. Longitudinal evidence shows that low T is allocated with a higher risk of subsequent development of MetS, although the reverse condition is also possible. Which are the factors in MetS responsible for the low T is not completely clarified. In clinical studies, increased waist circumference is the major determinant of MetS-associated hypogonadism. Our experiments in rabbits do not support the idea that visceral fat is the main determinant of MetS-associated male hypogonadism. Only few randomized clinical trials have evaluated the impact of T replacement therapy (TRT) in patients with MetS. Available evidence suggests that TRT decreases visceral fat accumulation and ameliorates insulin sensitivity, whereas androgen deprivation increases abdominal adiposity.

conclusionsThe clinical significance of the MetS-associated hypogonadism needs further clarifications. In particular, it has not been completely clarified if low T might be considered a cause or a consequence of MetS. The benefit of TRT in term of the reduction of CV risk needs to be confirmed in larger and longer studies.

Indexed as

AnimalsCardiovascular DiseasesClinical Trials as TopicErectile DysfunctionHumansHypogonadismKaplan-Meier EstimateMaleMEDLINEMetabolic SyndromeRisk FactorsTestosteroneTestosterone

Identifiers

PMID21720206
OpenAlexW2264199913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.